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ABSTRACT 
 
Genome research is emerging as a new and important tool in biology used to obtain 
information on gene sequences, genomic interaction, and how genes work in concert to 
produce the final syndrome or phenotype. Defect in phenylalanine hydroxylase (PAH) gene 
result in Phenylketonuria (PKU). Molecular studies using the brain of the mouse model for 
PKU (PAHenu2) showed altered expression of several genes including upregulation of orexin 
A and a low activity of branched chain aminotransferase. These studies suggest that a single 
gene (PAH) defect is associated with altered expression, transcription and translation of other 
genes. It is the combination of the primary gene defect, the altered expression of other genes, 
and the new metabolic environment that is created, which lead to the phenotype. 
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INTRODUCTION 
 
Phenylketonuria (PKU) is a common inborn 
error in aminoacid metabolism, with an 
average of 1 in 8000 U.S. Caucasians 
(DiLella et al., 1986). Deficiency of 
phenylalanine hydroxylase (PAH) affects 
normal conversion of phenylalanine to 
tyrosine. A deficiency of the activity of PAH 
causes PKU, which if untreated is 
characterized by high blood phenylalanine 
(Phe) levels and mental retardation 
(Eisensmith et al., 1991). 
 
Genome research has become an important 
new methodology used to investigate the 
complexity of the gene interaction (Lander et 
al., 2001; Venter et al., 2001). Functional 
genomics relies on determining changes in 
the levels of mRNA (the transcriptome), the 
levels of proteins or enzymes (the proteome), 
and the levels of metabolite concentrations 
resulting from such changes (the 
metabolome), affecting the function of a 
tissue or organ (Oliver, 1996). Deficiency of 
enzyme caused by mutations in the 
phenylalanine hydroxylase (PAH) gene 
(Antonarkis and McKusick, 2000; Jimenez-
Sanchez et al., 2001; Pey et al., 2003) leads 
to PKU. The regulatory, catalytic, tetrameric 
and BH4 binding regions of the PAH gene 
and mutations affecting the gene are shown 
in Figure 1. The mechanism causing mental 
retardation and the entire spectrum of 
neuropathology seen in the disease is unclear 
and cannot be explained by only the primary 
enzyme defect. 
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Fig 1: C-Alpha trace of a monomer of the composite model of phenylalanine hydroxylase 
(Matalon et al., 2004). Regulatory domain is colored in orange (residues 19-142), the 
catalytic domain in gray (residues 143-410), and the tetramerization domain (residues 411-
452) in blue.  Regions responsible for binding the BH4 cofactor are shown in purple. BH4 
cofactor is shown together with the iron at the active site. Side chain of the residues found to 
be BH4 responsive are shown mapped onto the structure. 
 
Mouse models are being used to investigate 
the cascade of events in the hierarchy of gene 
expression involved in human diseases 
(McDonald et al., 1990; Shefer et al., 2000) 
since there is close homology of the human 
and mouse genomes (Gunter and Dhand, 
2002; Madsen et al., 2001; Murphy et al., 
2001; Nadeau 2002; Waterson et al., 2002). 
Altered gene expression, transcription, 
translation and metabolites in the brain of the 
mouse model for PKU (BTBR-Pahenu2) is the 
subject of this study. 
 
THE MOUSE MODELS FOR PKU 
 
The mouse model for PKU (BTBR-Pahenu2) 
was produced using the alkylating agent N-
ethyl-N-nitrosourea (McDonald et al., 1990). 
The resulting PAH mutation was in the same 
locus observed in human patients. The 
mutation in the mouse caused a heritable 
inability to metabolize phenylalanine 
efficiently and the mouse model resembles 
very similar to human classical PKU in both 
initial genetic cause and ultimate phenotypic 
effects. The mouse leads to enzyme 
deficiency and increased blood and tissue 
levels of phenylalanine (Phe) as observed in 
the human counterpart (McDonald et al., 
1990). The phenotype also has features of the 
human disease, the coat color is lighter than 
in the normal mouse and the PKU mice are 
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 considered retarded. Therefore we studied 
genomic expression in the brain of the PKU 
mouse. 
 
EXPRESSION AND LEVELS OF 
OREXINS 
 
The mutation of PAH in the mouse model 
leads to altered expression of the orexin 
gene, causing an increase in the level of 
mRNA and the levels of orexin. Orexins 
(hypocretins) are recently discovered 
neuropeptides located mainly in the lateral 
hypothalamus of the brain (Nambu et al., 
1999; van den Pol, 1999). Orexin A 
(hypocretin 1) contains 33 amino acid 
residues and has a pyroglutamyl residue at 
the NH2 terminal and amide group at the 
COOH terminal. Orexin B (hypocretin 2) 
contains 28 amino acids and is 46% identical 
to orexin A (Sakurai et al., 1998). Both 
orexins are encoded by a single gene and the 
mRNA for the precursor peptide, prepro-
orexin, encodes 131 amino acid polypeptide 
(Sakurai et al., 1998). Orexins regulates 
various functions including arousal and food 
intake (Chemelli et al., 1999; Lu et al., 2000). 
Orexin deficiency was discovered in 
narcoleptic dogs and was found in humans 
with narcolepsy following diencephalic 
stroke (Scammell et al., 2001). There has 
been no report of any disease with increased 
production of orexin. 
 
The gene expression of the precursor for 
orexins, prepro-orexin, and the mRNA are 
upregulated in the PKU mouse brain (Table 
1). The high levels of mRNA for prepro-
orexin leads to increased orexin A levels in 
the PKU mouse brain (Table 2; Surendran et 
al., 2003, 2004). Phenylketonuria is the only 
disease showing higher level of brain orexin 
A. Since orexin is associated with 
wakefulness and increased activity and PKU 
patients are hyperactive, it is likely that 
orexin A level is affected in the brain of 
patient with PKU.  Orexins have not been 
studied in PKU and this may be an area of 
novel neurochemical research.  Plasma can 
also be used to study orexin levels, although 
the level of orexin in plasma is very low.  
Since orexin expression regulates sleep-wake 
cycle, a time dependent orexin expression 
study will be necessary. 
 
Table 1: Abnormal gene expression and mRNA levels in the PKU mouse brain 
A: Microarray expression analysis of the PKU mouse brain (Surendran et al. 2003, 2004) 
Gene bank 
accession no. 
Gene Expression ratio (in fold) 
AF 019566 Hypocretin 18.3↑ 
J00356 α –amylase-1 mRNA 6.4↑ 
M57647 Mast cell growth factor 
mRNA 
2.1↑ 
X05862 H2B and H2A histone genes 4.2↓ 
X16995 Hormone receptor 7.6↓ 
X14836 Calcium/calmodulin 
dependent 
Protein kinase II α 
2.5↓ 
 
B: Real time one step RT-PCR measurement of prepro-orexin mRNA in the PKU mouse 
Brain (n=7±S.E) normalized to 18S RNA and relative to mouse heart (fold changes) 
Wild type 2.19± 0.22 
PKU mouse 12.84± 1.76 
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 Mast cell growth factor (Viskochil, 2003), 
Hormone receptor (Ariznavarreta et al., 
2003) and α-amylase I (Callis and Ho, 1983; 
Takkinen et al., 1983) are involved in growth 
regulation. Calcium/calmodulin dependent 
protein kinase II α (Tombes et al., 2003) and 
H2B and H2A histone genes (Soto et al., 
2004) regulate cell signal (Table 1). Normal 
expression of these genes were altered by 
PAH mutation in the mouse. How these 
genes actions are synchronized to cause 
pathophysiology seen in the mouse is to be 
studied. 
 
Table 2: Levels of orexin A in the brain, heart and plasma of PKU and wild type mice 
(n=8±S.E; Surendran et al. 2003) 
 
Region Wild type (pg/mg protein) PKU (pg/mg protein) 
Cerebrum 689.37±40.73 2473.37±282.16 
Hypothalamus 540.87±93.09 3490.62±177.66 
Cerebellum 295.25±64.90 868.25±188.44 
Brainstem 414.37±59.74 3346.5±177.66 
Heart 276.75±21.78 696.37±57.24 
Plasma 138.8±26.58 223.0±27.04 
 
ALTERED ENZYME ACTIVITY IN 
THE PKU MOUSE BRAIN 
 
The hyperphenylalaninemia in PKU affects 
the transport of large neutral amino acids 
(LNAA) to the brain (Matalon et al., 2002, 
2003). The LNAA include phenylalanine, 
tyrosine, tryptophan, the branched amino 
acids: leucine, isoleucine, and valine among 
others. All LNAA use the same transporter to 
cross the blood brain barrier with 
phenylalanine having the highest affinity of 
binding to the transporter. Due to the high 
levels of Phe in the blood of patients with 
PKU, the entry of other LNAA to the brain is 
impeded (Matalon et al., 2002, 2003). We 
examined branched chain aminotransferase 
activity (BCAT), which is substrate 
dependent, in the brain of the PKU mouse. 
The enzyme BCAT catalyzes amino 
transferase for leucine, isoleucine, and 
valine, yielding the common intermediates 
acetyl-CoA and succinyl-CoA. Because of 
the low levels of branched chain amino acids 
in the PKU mouse brain, we examined the 
BCAT activity and indeed it was decreased.  
The activity of BCAT in the brain of the 
mouse model for PKU was 0.049±0.010 
mU/mg protein compared to the wild type, 
0.126±0.003. 
 
The high level of gene expression for orexin, 
the increased level of orexin, and the lower 
activity of BCAT in the PKU mouse model 
are examples of changes not directly related 
to the primary gene defect in PKU. These 
changes are responsible for a new 
biochemical environment for the brain. The 
low tyrosine level, caused by high level of 
blood Phe, decreases catecholamine synthesis 
in the PKU mouse brain (Pascucci et al., 
2002; Puglisi-Allegra et al., 2000; Table 3) 
as observed in human PKU (Curtis et al., 
1972; McKean, 1972; Partridge, 1998). 
These metabolic changes result in a new 
metabolome, which is the PKU phenotype 
that emerges. The quantitative expression of 
altered genes in the PKU mouse brain shows 
genomic interaction, which is likely similar 
to the human with PKU. 
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 Table 3: PAH gene mutation alters metabolites in the brain of mouse model for PKU (Pulgi-
Allegra et al. 2000) 
 
Brain regions 5-HT (ng/g wet 
weight) 
NE (ng/g wet weight) DA (ng/g wet weight) 
 Control PKU Control PKU Control PKU 
Prefrontal 
cortex 
851±33 234±19 495±13 252±12 117±8 42±5 
Cingulate 
cortex 
515±34 123±16 421±36 140±13 289±50 200±45 
Amygdala 1073±64 369±53 196±24 100±7 358±46 126±21 
Hippocampus 1255±77 299±21 556±14 237±17 112±21 101±19 
Nucleus 
accumbens 
1515±57 918±35 662±67 836±62 9766±433 6213±450 
Caudate 
putamen 
719±21 382±19 137±7 134±7 13074±369 9565±524 
5-HT - 5-hydroxytryptamine (serotonin), NE – norepinephrine, DA - dopamine 
 
 
CONCLUSION 
 
Functional genomic research yields new 
information on gene interaction and how the 
hierarchy of genes responds to the change in 
the levels of various proteins, so a new 
proteome is produced. Subsequently, the 
change of the proteome alters the normal 
metabolic environment of the metabolome, 
which also exerts an effect on gene 
expression and protein function. 
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